Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.45 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4661446 | 1.00 | LMNA (0.61) | LMNASMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL28450866 | 0.86 | LMNA (0.60) | LMNASMN1; SMN2KDM4EKMT2ANFKB1 | |
| SCHEMBL20603125 | 0.85 | LMNA (0.48) | LMNASMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL30379656 | 0.85 | LMNA (0.48) | LMNASMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL9233997 | 0.80 | LMNA (0.53) | LMNASMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL11669632 | 0.79 | SMN1; SMN2 (0.60) | LMNASMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL8544302 | 0.79 | SMN1; SMN2 (0.60) | LMNASMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL8544307 | 0.79 | SMN1; SMN2 (0.60) | LMNASMN1; SMN2KDM4EPKMKMT2A | |
| SCHEMBL1711226 | 0.79 | KDM4E (0.60) | LMNAKDM4EPKMKMT2AEGFR | |
| SCHEMBL1711227 | 0.79 | KDM4E (0.60) | LMNAKDM4EPKMKMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620102-B1 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | LMNA 3473/4885SMN1; SMN2 3620/4885KDM4E 1711/4885 |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | HCAR2, PCCA, MCCC2 | LMNA 2736/4885SMN1; SMN2 1969/4885KDM4E 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.